Chiral Technologies buys Diffinity Genomics

Published: 4-Aug-2015
Manufacturing Finance

Diffinity Genomics has developed novel technology for the purification of nucleic acids


Chiral Technologies, part of Daicel, the market leader in enantioselective chromatography, has bought the assets of Diffinity Genomics of West Henrietta, NY, US, for an undisclosed sum.

Diffinity Genomics has developed novel technology for the purification of nucleic acids, which formed the foundation for its products in DNA purification markets. The Diffinity RapidTip technology provides a method for rapid purification of amplified DNA fragments from Polymerase Chain Reaction (PCR) in a single step.

'The innovative, patented purification technology from Diffinity was a perfect choice for our expansion in the bio-separation/purification marketspace,' said Joseph Barendt, COO of Chiral Technologies.

As a new business unit of Chiral Technologies, Diffinity’s product portfolio demonstrates Chiral Technologies’ commitment to providing the health sciences industry with innovative separation technologies.

Upon the successful completion of the acquisition, Diffinity's CEO Joseph Marasco will leave the company to pursue other interests.

  • Companies:
  • Chiral Technologies
See more

You may also like

Manufacturing

Chiral Technologies introduces Chiralflash liquid chromatography columns

Read more
MPLC columns are packed with immobilised chiral stationary phases

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  3. Automate LC purification & high-purity compound recovery with UFPLC The purification instrument allows manufacturers to extract high-purity compounds in a shorter timeframe
  4. Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Chiral Technologies introduces Chiralflash liquid chromatography columns

MPLC columns are packed with immobilised chiral stationary phases
Manufacturing

Chiral Technologies gains rights to CSPs

Signs exclusive agreement with University of Vienna
Distribution

ChargePoint invest in a single-use manufacturing facility to expand product line

The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
Manufacturing

Optimising RNA production for faster and cheaper pharmaceutical manufacturing

RNA production can be a lengthy and complex process, but the Ntensify platform could change this by diminishing development times, decreasing production costs and allowing the avoidance of scaling issues
Manufacturing

Memel Biotech and Therabest collaborate to develop exosome-based cell therapies

The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Manufacturing

INEOS Nitriles launches INVIREO - the first bio-based acetonitrile

The company has released INVIERO, an acetonitrile capable of significantly reducing the carbon footprint of manufacturing processes
Research & Development

Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates

The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Subscribe now